Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Osiris Therapeutics, Inc.
  6. Summary
       US68827R1086

OSIRIS THERAPEUTICS, INC.
Delayed Nasdaq  - 
0.000000 USD    0.00%
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
 SummaryNewsCompany 
Company
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural... 
Read more
More about the company
All news about OSIRIS THERAPEUTICS, INC.
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Ther..
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
2019Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OS..
PR
2019ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.
PR
2019OSIRIS THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout
BU
2019Smith & Nephew to buy Osiris in regenerative products push
RE
2019OSIRIS THERAPEUTICS : Smith & Nephew expands in high growth regenerative medicine market t..
PR
2019Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
GL
2019HAGENS BERMAN : Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to ..
BU
2019OSIRIS THERAPEUTICS : Hagens Berman Notifies Osiris Therapeutics, Inc. Investors of Class ..
BU
2018Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief..
GL
2018Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
GL
2018Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
GL
2017Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
GL
More news
News in other languages on OSIRIS THERAPEUTICS, INC.
2016OSIRIS THERAPEUTICS : effectuera une présentation lors de la 26e Conférence de la European..
2016OSIRIS THERAPEUTICS : hält Präsentationen auf dem 26. Europäischen Wundkongress
More news
Managers and Directors
Samson Tom President & Chief Executive Officer
Laine Dyess Vice President-Sales
Heather Hill VP-Regulatory Affairs & Quality Assurance
Jeffrey Levin Vice President-Human Resources
Sector and Competitors
1st jan.Capi. (M$)
OSIRIS THERAPEUTICS, INC.40.67%0
GILEAD SCIENCES, INC.-11.38%79 850
REGENERON PHARMACEUTICALS, INC.8.63%73 473
VERTEX PHARMACEUTICALS22.26%68 632
WUXI APPTEC CO., LTD.-22.20%42 378
BIONTECH SE-36.69%39 666